0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > Complement C5

Complement C5

Complement C5 Molecule Information

Name:Complement C5
Target Synonym:Prepro-C5?CPAMD4?Complement C5?C3 And PZP-Like Alpha-2-Macroglobulin Domain-Containing Protein 4?C5D?Complement Component 5?C5a?Anaphylatoxin C5a Analog?C5a Anaphylatoxin?C5b?ECLZB?C5
Number of Launched Drugs:2
Number of Drugs in Clinical Trials:17
Lastest Research Phase:Approved

Complement C5 Protein Product ListCompare or Buy

By Product Status:
By Product Category:
By Tag:
By Conjugate:
Cat. No. Species Product Description Structure Purity Feature
CO5-R52H4 Rabbit Rabbit Complement C5 Protein, His Tag
CO5-R52H4-structure
CO5-R52H4-sds
CO5-H52H7 Human Human Complement C5 (w917s) Protein, His Tag
CO5-H52H7-structure
CO5-H52H7-sds
CO5-H52H7-elisa_1
CO5-H52Hx Human Human Complement C5 (R885H) Protein, His Tag
CO5-H52Hx-structure
CO5-H52Hx-sds
CO5-H52Hx-elisa_1
CO5-C52Hx Cynomolgus Cynomolgus Complement C5 Protein, His Tag
CO5-C52Hx-structure
CO5-C52Hx-sds
CO5-C52Hx-elisa_1
CO5-R52H5 Rat Rat Complement C5 Protein, His Tag
CO5-R52H5-structure
CO5-R52H5-sds
CO5-R52H5-elisa_1
CO5-M52H4 Mouse Mouse Complement C5 Protein, His Tag
CO5-M52H4-structure
CO5-M52H4-sds
CO5-M52H4-elisa_1
CO5-H52Ha Human Human Complement C5 Protein, His Tag
CO5-H52Ha-structure
CO5-H52Ha-sds
CO5-H52Ha-elisa_1

Complement C5 Part of Bioactivity data

CO5-H52Hx-ELISA
Human Complement C5 (R885H), His TagHuman Complement C5 (R885H), His Tag (Cat. No. CO5-H52Hx) ELISA bioactivity

Immobilized Human Complement C5 (R885H), His Tag (Cat. No. CO5-H52Hx) at 2 μg/mL (100 μL/well) can bind Anti-C5a (Human IgG1) with a linear range of 0.2-6 ng/mL (QC tested).

CO5-H52H7-ELISA
Human Complement C5 (w917s), His TagHuman Complement C5 (w917s), His Tag (Cat. No. CO5-H52H7) ELISA bioactivity

Immobilized Human Complement C5 (w917s), His Tag (Cat. No. CO5-H52H7) at 2 μg/mL (100 μL/well) can bind Anti-C5a MAb (Human IgG1) with a linear range of 0.2-6 ng/mL (QC tested).

Complement C5 Molecule Synonym Name

Complement C5,C5,CPAMD4

Complement C5 Molecule Background

Derived from proteolytic degradation of complement C5, C5 anaphylatoxin is a mediator of local inflammatory process. C5 precursor is first processed by the removal of 4 basic residues, forming two chains, beta and alpha, linked by a disulfide bond. C5 convertase activates C5 by cleaving the alpha chain, releasing C5a anaphylatoxin and generating C5b (beta chain + alpha' chain). Activation of C5 by a C5 convertase initiates the spontaneous assembly of the late complement components, C5-C9, into the membrane attack complex. C5b has a transient binding site for C6. The C5b-C6 complex is the foundation upon which the lytic complex is assembled. The C5a anaphylatoxin interacts with C5AR1 and tick complement inhibitor. C5a is also a potent chemokine which stimulates the locomotion of polymorphonuclear leukocytes and directs their migration toward sites of inflammation.

Complement C5 References

Complement C5 Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Eculizumab 5G1-1; HAL-1; LEX-98; h-5G1.1 Approved Alexion Pharmaceuticals Inc Soliris Mainland China Atypical Hemolytic Uremic Syndrome; Hemoglobinuria, Paroxysmal s:18:"Alexion Europe Sas"; 2007-03-16 Myasthenia Gravis; Hemoglobinuria, Paroxysmal; Atypical Hemolytic Uremic Syndrome; Delayed Graft Function; Neuromyelitis Optica; Asthma Details
Ravulizumab ALXN-1210; ALXN-1810 Approved Alexion Pharmaceuticals Inc Ultomiris EU Hemoglobinuria, Paroxysmal s:18:"Alexion Europe Sas"; 2018-12-21 Myasthenia Gravis; Hemoglobinuria, Paroxysmal; Glomerulonephritis, IGA; Coronavirus Disease 2019 (COVID-19); Respiratory Distress Syndrome, Adult; Atypical Hemolytic Uremic Syndrome; Thrombotic Microangiopathies; Lupus Nephritis; Pneumonia, Viral; Neuromyelitis Optica; Amyotrophic Lateral Sclerosis; Acute Lung Injury Details

Complement C5 Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
Eculizumab biosimilar (IBC GENERIUM) Phase 3 Clinical Ibc Generium Hemoglobinuria, Paroxysmal; Atypical Hemolytic Uremic Syndrome Details
Tesidolumab NOV-4; LFG-316 Phase 2 Clinical Novartis Pharma Ag, Morphosys Ag Hemoglobinuria, Paroxysmal; Wet Macular Degeneration; Geographic Atrophy; Macular Degeneration Details
Eculizumab biosimilar (Samsung Bioepis) SB-12 Phase 3 Clinical Samsung Bioepis Hemoglobinuria, Paroxysmal Details
Nomacopan EV-576; rVA576; rEV-576 Phase 3 Clinical Evolutec Myasthenia Gravis; Hemoglobinuria, Paroxysmal; Arthritis, Rheumatoid; Sjogren's Syndrome; Autoimmune Diseases; Atypical Hemolytic Uremic Syndrome; Hemolytic-Uremic Syndrome; Asthma; Keratoconjunctivitis; Inflammation; Guillain-Barre Syndrome Details
Eculizumab biosimilar (CinnaGen) Phase 3 Clinical Cinnagen Hemoglobinuria, Paroxysmal Details
ALXN-5500 ALXN-5500 Phase 1 Clinical Alexion Pharmaceuticals Inc Hemoglobinuria, Paroxysmal Details
Pozelimab REGN-3918 Phase 3 Clinical Regeneron Pharmaceuticals Inc Hemoglobinuria, Paroxysmal Details
Eculizumab biosimilar (Amgen) ABP-959 Phase 3 Clinical Amgen Inc Hemoglobinuria, Paroxysmal; Hemolytic-Uremic Syndrome Details
Zilucoplan RA-101495; RA-101495-SC Phase 3 Clinical Ra Pharma Myasthenia Gravis; Hemoglobinuria, Paroxysmal; Lupus Nephritis; Hemolytic-Uremic Syndrome Details
Cemdisiran ALN-CC5 Phase 2 Clinical Alnylam Pharmaceuticals Inc Glomerulonephritis, IGA; Hemoglobinuria, Paroxysmal; Atypical Hemolytic Uremic Syndrome; Hemolytic-Uremic Syndrome Details
Crovalimab SKY-59; RG-6107; CH-7092230; RO-7092230; RO-7112689; RO-7112689/F01 Phase 3 Clinical F. Hoffmann-La Roche Ltd, Chugai Pharmaceutical Co Ltd Hemoglobinuria, Paroxysmal Details
Eculizumab biosimilar (Biocad) BCD-148 Phase 3 Clinical Biocad Hemoglobinuria, Paroxysmal Details
BDB-001 BDB-001; BDB001; BDB 001 Phase 3 Clinical Staidson(Beijing) Biopharmaceuticals Co Ltd Coronavirus Disease 2019 (COVID-19); Neoplasms; Hidradenitis Suppurativa Details
Vilobelimab IFX-1; CaCP-29 Phase 3 Clinical Beijing Mabworks Biotech Co Ltd, Inflarx Shock, Septic; Granulomatosis with Polyangiitis; Pyoderma Gangrenosum; Microscopic Polyangiitis; Sepsis; Coronavirus Disease 2019 (COVID-19); Hidradenitis Suppurativa; Systemic Inflammatory Response Syndrome Details
Avacincaptad pegol ARC-187; ARC-1905 Phase 3 Clinical Archemix Geographic Atrophy; Stargardt Disease; Macular Degeneration Details
Olendalizumab ALXN-1007 Phase 2 Clinical Alexion Pharmaceuticals Inc Graft vs Host Disease; Antiphospholipid Syndrome; Rejection of organ transplantation; Inflammation Details
ALXN-1720 ALXN-1720 Phase 1 Clinical Alexion Pharmaceuticals Inc Details

This web search service is supported by Google Inc.

totop